Northern Advantage: 
Canada's Federal Court as a Venue for Pharmaceutical Patent Litigation

In the complex and high-stakes world of pharmaceutical patent litigation, selecting the right venue can significantly influence the outcome of a case. For companies marketing or seeking to market pharmaceuticals in Canada, the Federal Court stands out as a preferred forum for resolving disputes related to pharmaceutical patents. This blog explores the unique benefits of choosing Canada’s Federal Court as a venue for pharmaceutical patent litigation, highlighting its specialized expertise, procedural efficiency and precedent-based outcomes.

Specialized Expertise in Patent Law

The Federal Court is the preferred venue for adjudicating patent disputes in Canada due to its country-wide jurisdiction and specialized expertise.

The country-wide jurisdiction of the Federal Court gives it the ability to grant relief throughout Canada in a single proceeding regarding infringement and/or invalidity issues. Provincial superior courts may hear actions for infringement within their borders, but may not hear impeachment actions and if infringement occurs across several provinces, a litigant must sue in each province. For these reasons, the Federal Court is typically chosen as the Canadian venue to litigate patent matters.

The Federal Court of Canada has developed a robust reputation for its expertise in patent law, particularly in the pharmaceutical patent sector. Beginning in 2023, the Federal Court established specialized Chambers of the Court, including an Intellectual Property and Competition chambers. Federal Court Judges with expertise in intellectual property law are often assigned to this chambers, and frequently preside over patent disputes, including those involving complex pharmaceutical technologies. This experience equips them with a deep understanding of the scientific, technical and legal nuances that are often central to such cases. Accordingly, parties involved in patent litigation before the Federal Court can confidently expect that the judges presiding over their cases have expertise in the relevant subject matter.

Procedural Efficiency and Streamlined Litigation

Pharmaceutical patent litigation often involves time-sensitive issues, such as the launch of subsequent-entry drugs. In Canada, pharmaceutical patent cases are often brought under the Patented Medicines (Notice of Compliance) Regulations (the Regulations), which is the regime that links approval of subsequent-entry drugs to the patent status of a reference drug. Certain cases brought under the Regulations create a 24 month "stay" where the subsequent-entry drug cannot be approved for sale by Health Canada during that period.

The Federal Court is well-suited to handle cases brought under the Regulations efficiently due to streamlined procedures and case management practices. Key features include:

• Case Management: A case management judge is assigned to cases under the Regulations, which allows a judicial officer, usually an Associate Judge, to familiarize himself or herself with the file, preside over case conferences and hear and decide certain pre-trial motions. Case conferences allow parties to address procedural issues early in the litigation process, ensuring that cases proceed smoothly and without unnecessary delays.
• Early Disclosure and Robust Discovery Rights: a subsequent-entry manufacturer is obliged to disclose at an early stage documents from its drug submission that allow the manufacturer of the reference drug to assess potential non-infringement allegations. All parties to the litigation have a positive obligation to produce relevant, non-privileged documents in their power, possession or control and to make a corporate representative available for an examination under oath. The named inventor(s) of any patents at issue may also be examined for discovery.
• Confidentiality Safeguards: many cases under the Regulations will have a Protective Order governing the treatment of a counterparty's designated confidential information as between the parties. These Protective Orders often limit the number of employees of a party that may access the counterparty's confidential information. Although Canada has a strong open courts principle, Confidentiality Orders may also be granted by the Court to allow certain aspects of court filings and hearings to be sealed from the public.
• Timely Decisions: The Federal Court is known for its commitment to delivering timely judgments, which is critical in the pharmaceutical industry where market exclusivity and regulatory timelines are at stake. This is particularly so in certain cases brought under the Regulations, which are typically adjudicated in under 24 months as otherwise the "stay" will lift and Health Canada may grant marketing authorization to the subsequent-entry drug.

Precedent-Based Decision-Making

The Federal Court's extensive body of jurisprudence in pharmaceutical patent cases provides a level of predictability that is invaluable to litigants. Decisions are grounded in well-established legal principles, and the Court often references its own precedents, fostering consistency in its rulings and the respect for the common law and stare decisis.

Key Trends for 2026

Canadian IP practitioners are focused on the following key areas of development in 2026:

• Patentable Subject Matter: in October 2025, the Supreme Court of Canada heard oral argument in Pharmascience v Janssen Inc, which will answer whether or not a method of medical treatment comprises patentable subject matter. The Court reserved its decision and it is expected to be released by Q3 2026.
• Anticipation: the law of anticipation in Canada has typically been addressed by comparing a single document to the claim(s) of the patent(s) at issue. However, a 2025 Federal Court decision has opened debate about whether anticipation ought to be assessed through the lens of a single "disclosure" as opposed to a single "document".
• Overbreadth: since 2021, overbreadth has been consistently recognized by the Federal Court of Appeal as an independent ground of patent invalidity. However, its application continues to develop, with a 2026 decision emphasizing the importance of the patent's disclosure to determine that which was invented, even where the statements in the patent disclosure were different from the testimony of the inventor himself.
• Section 8 Damages: if a subsequent-entry manufacturer succeeds in a case brought under the Regulations, it may be entitled to compensation for damages for the period of time it was kept off the market during the 24-month "stay". The scope of section 8 damages was expanded by amendments to the Regulations in 2017, but a case under this modified provision has yet to proceed through to a trial decision.

Conclusion

Choosing the Federal Court of Canada as a venue for pharmaceutical patent litigation offers a range of strategic advantages, from specialized judicial expertise to procedural efficiency and precedent-based outcomes. For pharmaceutical companies navigating the complexities of patent disputes, the Federal Court provides a forum that is not only well-equipped to handle the technical and legal challenges of these cases but also aligned with the broader goals of innovation and market fairness.

As the pharmaceutical industry continues to evolve, the Federal Court's role as a cornerstone of Canada’s patent litigation landscape will remain critical. Companies seeking to protect their innovations and enforce their patent rights would do well to consider the Federal Court of Canada as their venue of choice.

Please note that this publication presents an overview of notable legal trends and related updates. It is intended for informational purposes and not as a replacement for detailed legal advice. If you need guidance tailored to your specific circumstances, please contact one of the authors, the Intellectual Property group or the Commercial Litigation group to explore how we can help you navigate your legal needs.